NCT05084027

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: First Affiliated Hospital of Zhejiang University · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

Detailed description

It was a phase Ⅱ clinical trial of new designed reduced-intensity conditioning regimen for older patients accepting allogeneic hematopoietic stem cell transplantation treatment. The regimen consisted of venetoclax combining with fludarabine and melphalan.

Conditions

• Hematologic Malignancy
• Older Patients
• Allogeneic Hematopoietic Stem Cell Transplantation

Interventions

Type	Name	Description
COMBINATION_PRODUCT	venetoclax combining with fludarabine and melphalan	Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2

Timeline

• Start date: 2021-10-07
• Primary completion: 2022-09-30
• Completion: 2024-09-30
• First posted: 2021-10-19
• Last updated: 2021-10-27

Locations

8 sites across 1 country: China